Teva Confirms Denosumab Is Part Of Its Biosimilar Pipeline
Prolia Biosimilar Asset Is In Phase III Development
Executive Summary
Teva has officially confirmed one of its many biosimilar assets is a rival to Amgen’s Prolia (denosumab) to treat osteoporosis in postmenopausal women. Sandoz, Celltrion and Samsung Bioepis are among those that have previously thrown their hats into the ring.
You may also be interested in...
Alvotech Makes It Four With Denosumab Trial
Alvotech has begun its fourth biosimilar clinical trial program, announcing the start of studies for its AVT03 proposed denosumab rival to Prolia/Xgeva.
Biocon Joins Fray For Denosumab, Ustekinumab Biosimilars
Biocon is progressing trials for biosimilar rivals to Amgen’s Prolia/Xgeva (denosumab) and J&J’s Stelara (ustekinumab), even as it gears for other large opportunities coming its way via the Viatris deal including for blockbusters Humira and Eylea.
Biocon Joins Fray For Denosumab, Ustekinumab Biosimilars
Biocon is progressing trials for biosimilar rivals to Amgen’s Prolia/Xgeva (denosumab) and J&J’s Stelara (ustekinumab), even as it gears for other large opportunities coming its way via the Viatris deal including for blockbusters Humira and Eylea.